Want to see JP:7634 full AI Analyst Report?
Top Page
Hoshi Iryosanki Co., Ltd.
(7634)
Select Model
Select Model
Rating:76Outperform
Price Target:
¥5,797.00
▲(13.44% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by solid financial performance—especially the low-leverage balance sheet and steady operating profitability—plus supportive valuation (low P/E and a dividend). Technical indicators are mixed, with longer-term trend support but near-term softness and weak stochastic momentum, which tempers the overall rating.
Positive Factors
Steady Revenue and Operating Profitability
The company has expanded its revenue base while preserving solid operating profitability. This combination indicates an established distribution franchise and suggests that its healthcare-provider relationships can support durable earnings over the next several quarters.
Negative Factors
Moderate Revenue Growth Pace
Although revenue has grown over time, the reported growth rate is modest. A slower expansion pace may limit operating leverage and make future earnings increasingly dependent on margin management, product mix, or gains in the domestic healthcare market.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue and Operating Profitability
The company has expanded its revenue base while preserving solid operating profitability. This combination indicates an established distribution franchise and suggests that its healthcare-provider relationships can support durable earnings over the next several quarters.
Read all positive factors
Hoshi Iryosanki Co., Ltd. (7634) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥16.38B
Dividend Yield1.7%
Average Volume (3M)1.10K
Price to Earnings (P/E)11.9
Beta (1Y)0.06
Revenue Growth2.05%
EPS Growth-8.63%
CountryJP
Employees527
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)445.54
Shares Outstanding3,420,000
10 Day Avg. Volume1,120
30 Day Avg. Volume1,096
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)0.82
Price to Sales (P/S)1.06
P/FCF Ratio7.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hoshi Iryosanki Co., Ltd. Business Overview & Revenue Model
Company Description
Hoshi Iryo-Sanki Co., Ltd., a Japanese firm, specializes in the production and distribution of pharmaceutical-grade medical oxygen and nitrous oxide. Its business activities are structured across five distinct divisions: Medical Gas, Home Healthca...
How the Company Makes Money
The company primarily makes money by selling and distributing medical devices and healthcare-related products to medical institutions in Japan. Revenue is generated mainly from (1) product sales (i.e., wholesaling/distribution margins earned betwe...
Hoshi Iryosanki Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.56B | 15.52B | 15.10B | 14.78B | 13.78B | 12.77B |
| Gross Profit | 7.70B | 7.39B | 7.31B | 6.96B | 6.51B | 6.03B |
| EBITDA | 2.97B | 2.87B | 2.81B | 2.86B | 2.71B | 2.48B |
| Net Income | 1.39B | 1.37B | 1.46B | 1.40B | 1.25B | 1.11B |
Balance Sheet | ||||||
| Total Assets | 26.53B | 26.74B | 24.59B | 23.04B | 21.25B | 20.25B |
| Cash, Cash Equivalents and Short-Term Investments | 11.27B | 11.21B | 10.63B | 9.76B | 9.03B | 8.76B |
| Total Debt | 946.35M | 1.28B | 1.09B | 834.44M | 1.00B | 1.29B |
| Total Liabilities | 6.09B | 6.42B | 5.87B | 5.66B | 5.66B | 5.74B |
| Stockholders Equity | 20.13B | 20.01B | 18.43B | 17.10B | 15.37B | 14.29B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.16B | 1.65B | 2.15B | 1.89B | 1.40B |
| Operating Cash Flow | 0.00 | 2.48B | 2.19B | 2.40B | 2.29B | 1.97B |
| Investing Cash Flow | 0.00 | -1.54B | -5.28B | -744.85M | -1.06B | -690.26M |
| Financing Cash Flow | 0.00 | -948.38M | -739.64M | -902.90M | -957.69M | -936.90M |
Hoshi Iryosanki Co., Ltd. Technical Analysis
Positive
5110.00
Price Trends
5077.60
Positive
5076.80
Positive
5048.61
Positive
Market Momentum
51.43
Negative
68.62
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7634, the sentiment is Positive. The current price of 5110 is below the 20-day moving average (MA) of 5235.00, above the 50-day MA of 5077.60, and above the 200-day MA of 5048.61, indicating a bullish trend. The MACD of 51.43 indicates Negative momentum. The RSI at 68.62 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7634.
Hoshi Iryosanki Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥17.78B | 11.98 | ― | 3.02% | 20.88% | 44.61% | |
76 Outperform | ¥16.38B | 11.90 | ― | 1.61% | 2.05% | -8.63% | |
61 Neutral | ¥6.09B | 15.13 | ― | ― | 11.17% | ― | |
59 Neutral | ¥16.19B | 17.64 | ― | 2.65% | 2.22% | -2.17% | |
55 Neutral | ¥15.21B | 16.84 | ― | 2.32% | 8.19% | -25.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥21.83B | -96.89 | ― | 3.12% | -6.64% | 67.08% |
* Healthcare Sector Average
JP:7634
Hoshi Iryosanki Co., Ltd.
5,300.00
659.99
14.22%
JP:4350
Medical System Network Co., Ltd.
500.00
37.97
8.22%
JP:6678
Techno Medica Co., Ltd.
2,118.00
188.32
9.76%
JP:7600
Japan Medical Dynamic Marketing, Inc.
807.00
298.39
58.67%
JP:7707
Precision System Science Co.,Ltd
219.00
14.00
6.83%
JP:7743
Seed Co., Ltd.
635.00
103.08
19.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.